CARDIOVASCULAR JOURNAL OF AFRICA • Vol 21, No 3, May/June 2010
136
AFRICA
1997;
153
: 185–192.
Hertog MG., Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary
3.
antioxidant flavonoids and risk of coronary heart disease: The Zutphen
Elderly Study.
Lancet
1993;
342
: 1007–1011.
Hertog MG., Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza
4.
F,
et al
. Flavonoid intake and long-term risk of coronary heart disease
and cancer in the seven countries study.
Arch Int Med
1995;
155
:
381–386.
Renaud SC, Gueguen R, Schenker J, D’Houtaud A. Alcohol and mortal-
5.
ity in middle-aged men from eastern France.
Epidemiology
1998;
9
:
184–188.
Renaud SC, Gueguen R, Siest G., Salamon R. Wine, beer, and mortal-
6.
ity in middle-aged men from eastern France.
Arch Int Med
1999;
159
:
1865–1870.
Middleton E (jun), Kandaswami C, Theoharides CT. The effects of plant
7.
flavonoids on mammalian cells: implications for inflammation, heart
disease and cancer.
Pharmacol Rev
2000;
52
: 673–751.
Chen CK, Pace-Asciak CR. Vasorelaxing activity of resveratrol and
8.
quercetin in isolated rat aorta.
Gen Pharmacol
, 1996;
27
: 363–366.
Formica JV, Regelson W. Review of the biology of quercetin and related
9.
bioflavonoids.
Food Chem Toxicol
1995;
33
: 1061–1080.
Duarte J, Galisteo M, Ocete MA, Pérez-Vizcaíno F, Zarzuelo A,
10.
Tamargo J. Effects of chronic quercetin treatment on hepatic oxidative
status of spontaneously hypertensive rats.
Molec Cell Biochem
2001;
221
: 155–160.
Duarte J, Pérez-Palencia R, Vargas F, Pérez-Vizcaíno F, Zarzuelo A,
11.
Tamargo J. Antihypertensive effects of the flavonoid quercetin in sponta-
neously hypertensive rats.
Br J Pharmacol
2001;
133
:117–124.
Ferrell JE, Sing PDC, Loew G., King R, Mansour JM, Mansour TE.
12.
Structure-activity studies of flavonoids as inhibitors of cyclic AMP
phosphodiesterase and relationship to quantum chemical indices.
Molec
Pharmacol
1979;
16
: 556–568.
Landolfi R, Mower RL, Steiner M. Modification of platelet function
13.
and arachidonic acid metabolism by bioflavonoids: structure-activity
relations.
Biochem Pharmacol
1984;
33
: 1525–1530.
Ortmann R, Nutto D, Waldmeyer J. Phloretin and related compounds
14.
inhibit agonist-stimulated cAMP accumulation in cultured cells of CNS
origin.
Biochem Pharmacol
1979;
28
: 2357–2361.
Ruckstuhl M, Landry Y. Inhibition of lung cyclic AMP- and cyclic
15.
GMP-phosphodiesterase by flavonoids and other chromone-like
compounds.
Biochem Pharmacol
1981;
30
: 697–702.
Whitten PL, Naftolin F. Dietary oestrogens: a biologically active back-
16.
ground for oestrogen action. In: Hochberg RB, Naftolin F, eds.
The New
Biology of Steroid Hormones.
NewYork: Raven Press, 1991: 155–167.
Lozoya X, Meckes M, Aboud-Zaid M, Tortoriello J, Nozolillo C, Amason
17.
JT. Quercetin glycosides in
Psidium guajava
L. leaves and determination
of a spasmolytic principle.
Arch Med Res
1994;
25
:11–15.
Hagiwara M, Inoue S, Tanaka T, Nunoki K, Ito M, Hidaka H. Differential
18.
effects of flavonoids as inhibitors of tyrosine protein kinases and serine-
threonine protein kinases.
Bioch Pharmacol
1988;
37
: 2987–2999.
Pérez-Vizcaíno F, Ibarra M, Cogolludo AL, Duarte J, Zaragozaírnaéz
19.
F, Moreno L,
et al
. Endothelium-independent vasodilator effects of
the flavonoid quercetin and its methylated metabolites in rat conduct-
ance and resistance arteries.
J Pharmacol Exp Therapeut
2002;
302
(1):
66–72.
Rogers JC, Williams DL. Kaempferol inhibits myosin light chain kinase.
20.
Biochem Biophys Res Commun
1989;
164
: 419–425.
Beretz A, Anton R, Stoclet J. Flavonoid compounds are potent inhibitors
21.
of cyclic AMP phosphodiesterase.
Experientia
1978;
34
: 1054–1055.
Beretz A, Stoclet J, Anton R. Inhibition of rat isolated aorta contraction
22.
by flavonoids. Possible correlation with cAMP-phosphodiesterase inhi-
bition.
Planta Medica
1980;
39
: 236.
Petkov E, Uzunov P, Kostova I, Somleva T, Ognyanov I. Inhibition of rat
23.
heart phosphodiesterase by some rotenoids and isoflavonoids.
Planta
Medica
1983;
47
: 237–239.
Duarte J, Pérez-Vizcaíno F, Jimenez J, Tamargo J, Zarzuelo A.
24.
Vasodilatory effects of flavonoids in rat aortic smooth muscle. Structure-
activity relationships.
Gen Pharmacol
1993;
24
: 857–862.
Duarte J, Pérez-Vizcaíno F, ZarzueloA, Jimenez J, Tamargo J. Vasodilator
25.
effects of quercetin on isolated rat vascular smooth muscle.
Eur J
Pharmacol
1993;
239
: 1–7.
Chan ECH, Pannangpetch P, Woodman OL. Relaxation of flavones and
26.
flavonols in rat isolated thoracic aorta: mechanism of action and struc-
ture-activity relationships.
J Cardiovasc Pharmacol
2000;
35
: 326–333.
Herrera MD, Zarcuelo A, Jimdnez J, Marhuenda E, Duarte J. Effects of
27.
flavonoids on rat aortic smooth muscle contractility: structure-activity
relationships.
Gen Pharmacol
1996;
27
(2): 273–277.
Ethics Committee.
28.
Guide to the Care and Use of Laboratory Animals in
Research and Teaching.
Durban: University of KwaZulu-Natal, 2009.
Revuelta MP, Cantabrana B, Hidalgo A. Depolarization-dependent effect
29.
of flavonoids in rat uterine smooth muscle contraction elicited by CaCI
2
.
Gen Pharmacol
1997;
29
(5): 847–857.
Navasa M, Bosch J, Rhodes J. Pharmacological agents and portal hyper-
30.
tension. In: Okuda K, Benhamou JP, eds.
Portal Hypertension: Clinical
and Physiological Aspects
. Berlin: Springer Verlag, 1991: 35–49.
Ajay M, Achike FI, Mustafa AM, Mustafa MR. Effect of quercetin on
31.
altered vascular reactivity in aortae isolated from streptozotocin-induced
diabetic rats.
Diabetes Res Clin Prac
2006;
73
: 1–7.
Rice-Evans A, Packer L.
32.
Flavonoids in Health and Disease
. New York:
Marcel Dekker Inc, 1998.
It's the
shell that
makes
safer.
Safety-Coated
R
81mg
The ORIGINAL low dose aspirin
for optimum cardio-protection
Hp
Each tablet contains Aspirin 81mg. Reg.No.: 29/2.7/0767
Pharmafrica (Pty) Ltd, 33 Hulbert Road, New Centre, Johannesburg 2001
Under licence from Goldshield Pharmaceuticals Ltd. U.K.
